Table 1:
Demographics for study participants
| Characteristic | Regimen I N(%) | Regimen II N(%) | Regimen III N(%) | Total N(%) |
|---|---|---|---|---|
| Age (y) | ||||
| ≤40 | 9 (5.2) | 7 (5.4) | 6 (4.9) | 22 (5.2) |
| 40–49 | 29 (16.8) | 16(12.5) | 26(21.1) | 71 (16.7) |
| 50–59 | 60 (34.7) | 47 (36.7) | 42(34.1) | 149(35.1) |
| 60–69 | 54(31.2) | 41 (32) | 40 (32.5) | 135(31.8) |
| 70–79 | 21 (12.1) | 16(12.5) | 9 (7.3) | 46(10.8) |
| ≥80 | 0 | 1 (0.8) | 0 | 1 (0.2) |
| BRCA 1 or 2 | ||||
| BRCA+ | 18(10.3%) | 16(12.2%) | 25(19.8%) | 59 (13.7%) |
| BRCAwt | 90(51.7%) | 61(46.6%) | 59(46.8%) | 210 (48.7%) |
| Unknown | 66(37.9%) | 54(41.2%) | 42(33.3%) | 162 (37.6%) |
| Race | ||||
| White | 154 (89) | 113(88.3) | 115(93.5) | 382(90.1) |
| Black | 7 (4.0) | 8 (6.3) | 4(3.3) | 19 (4.5) |
| Asian | 8 (4.6) | 3 (2.3) | 3 (2.4) | 14 (3.3) |
| Am Indian | 1 (0.6) | 0 | 0 | 1 (0.2) |
| Ukn | 3(1.7) | 4(3.1) | 1 (0.8) | 8(1.9) |
| Performance Status | ||||
| 0 | ||||
| 1 | 118(68.2) | 83 (64.8) | 87 (70.7) | 288 (67.9) |
| 2 | 54(31.2) | 43 (33.6) | 36 (29.3) | 133(31.4) |
| 1 (0.6) | 2(1.6) | 0 | 3 (.7) | |
| Histology | ||||
| Serous | 128 (74) | 100(78.1) | 101 (82.1) | 329 (77.6) |
| Endometrioid | 15(8.7) | 7 (5.5) | 10(8.1) | 32 (7.5) |
| Clear Cell | 14(8.1) | 7 (5.5) | 4 (3.3) | 25 (5.9) |
| Other | 16 (9.3) | 14(10.9) | 8 (6.5) | 38 (9.0) |
| Stage | ||||
| 2 | 24 (14%) | 19(15%) | 10 (8%) | 53 (12.5%) |
| 3 | 119(69%) | 83 (65%) | 104 (85%) | 306 (72.5%) |
| 4 | 30 (17%) | 26 (20%) | 9 (7%) | 65 (15%) |
| Residual Disease | ||||
| >0 cm | 54(31%) | 47 (35.9%) | 21(16.7%) | 122(28.3%) |
| Microscopic | 120 (68.9%) | 84 (64%) | 105 (83.3%) | 309(71.7%) |
Am Indian = American Indian; Ukn = unknown; NOS = not otherwise specified